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Steatosis is the most common hepatic lesion associated with CF. It does not appear
to be directly related to the CF secretory defect. It is unclear whether hepatic
steatosis progresses to ﬁbrosis. TGFbs are multifunctional cytokines that regulate
proliferation and differentiation of a wide spectrum of cells. TGFbs signal through
transmembrane threonine-kinase receptors, activating intracellular mediators, called
SMADs, which modulate the transcription of target genes. The aim of this study
was to investigate the contribution of TGFb cytokines to the steatosis and ﬁbrosing
process in CF.
Methods: Liver disease (LD) was demonstrated in 12 CF patients, who had a mean
age of 12.5 years and underwent percutaneous liver biopsy with the biopsy needle
directed to the site of the lesion with the aid of CT scan. Hepatic tissue mRNA
levels of TGFb1, TGFb2, TGFb3, CTGF, ALK5 and Smad2, 3, 4, 7 were estimated
by quantitative real-time RT-PCR.
Results: There was no correlation between the expression of TGF-bs, ALK5, Smads
and CTGF and steatosis (TGFb1/steatosis p: 0.8830, TGFb2/steatosis p: 0.8652,
TGFb3/steatosis p: 0.7422, ALK5/steatosis p: 0.8741, Smad2/steatosis p: 0.7856,
Smad3/steatosis p: 0.9009, Smad4/steatosis p: 0.2618, Smad7/steatosis p: 0.8474,
CTGF/steatosis p: 0.7944). There was signiﬁcant correlation, however, between the
inﬂammation grade and steatosis (p: 0.0386) as well as tendency of correlation
between ﬁbrosis and steatosis (p: 0.0828).
Conclusion: The pathway of TGF-SMADs contributes to the ﬁbrosing process of
CFLD. There is an increase in the degree of inﬂammation and ﬁbrosis in association
with steatosis. Steatosis is a condition that may lead to inﬂammation and, ﬁnally,
to ﬁbrosis in the CFLD.
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In Polish CF Registry there are 1440 alive pts. Some of them will need LT.
Aim: To evaluate 10-year outcome of LT in CF pts.
Methods: Out of >500 LTs performed in our hospital, 10 LTs were carried out in CF
pts between 2001–2011.
Results: The table presents data of 9 alive pts only. 10 yr female pt operated 2003
died 2 mths after reLT as result of allograft rejection.
Table: Patients’ characteristics
Pt/
Gender
Age CFTR mutations Waiting
time
(mo)
Allografts FEV1
pre/post
(%pred)
BMI
pre/post
Bacterial
colonization
pre/post
Immuno-
suppressive
drugs
Survival
time (yr)
1/M 19 F508del/F508del 6 LRD
(mother)
91/50 14.6/18.7 Pa,Sa/Pa T 11
2/M 17 F508del/G542 12 CAD 104/89 14.6/19.3 Hi/Sa C 9.9
3/F 21.6 F508del/R553X 32 CAD 62/59 17.1/19.6 Sa/Sa(Pa) T 7.9
4/M 24 F508del/F508del 1 CAD 103/85 18.8/19.7 Pa,Sa/Pa,Sa T, Mm 6
5/M 9.9 F508del/R437P 2 CAD 131/90 14.0/14.1 Sa/Sa,(Pa) T, Mm 3.4
6/M 14.9 F508del/F508del 6 CAD 80/82 17.1/17.6 Sa/Sa T, Mm 2.6
7/M 10 F508del/F508del 6 LRD
(father)
77/80 15.6/16.8 Sa/Sa T, Mm 2
8/F 16 F508del/F508del 1 CAD 93/87 20.2/18.6 Sa/Ec T, Mm 1.4
9/M 15.9 F508del/2143delT 11 CAD 91/84 17.5/15.7 Sa,Hi/Sa T, Mm 0.6
CAD, cadaveric donor; LRD, living related donor.
Hi, Haemophilus inﬂuenzae; Pa, Pseudomonas aeruginosa; Sa, Staphylococcus aureus.
C, Ciclosporine; Mm, Mycophenolate mofetil; T, Tacrolimus.
The most frequent mutation in pts after LT is F508del. 7 LTs were from cadaveric
donors (CAD), 2 LTs were from live related donors (LRD). The dominant pathogen in
the airways before/after LT is Staphylococcus aureus (Sa). We have not observed more
frequent Pseudomonas aeruginosa (Pa) chronic colonization except for intermittent col-
onization in pts 3, 5. All pts receive immunosuppresive treatment with Tacrolimus (T),
Ciclosporine (C), Mycophenolate mofetil (Mm). The following complications occurred:
thrombosis of hepatic artery (pt 3), acute rejection (pts 4, 8), renal insufﬁciency (pt 4),
biliary complications (pts 1, 2, 6, 8), diabetes (pts 1, 3, 8).
Conclusions: Respiratory status has remained unchanged exept pt 1. The nutritional
status has improved only in pts 1, 2 (10 yrs after LT). LT seems to be effective treatment
for CFLD.
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Hepatitis E virus infection (HEV) can evolve into chronic infection and lead to
cirrhosis and end-stage liver disease in immunocompromised patients.
Objectives: We reported 3 lung transplant patients for Cystic Fibrosis (CF) and
persistent HEV infection.
Methods: The diagnosis of HEV was suspected because chronic (2−24 months)
unexplained liver tests abnormalities. Two of these patients were seropositive (IgM
HEV), the diagnosis in the seronegative third one was conﬁrmed on positive HEV
viremia. This patient had received Bortezumib for acute humoral rejection. All
patients had HEV genotype 3. One patient had abnormal hepatocellular function
associated with the development of liver ﬁbrosis, attested by elastometry (e = 13 kPa
and one year later 45 kPa) and liver biopsy (Metavir score F2 to F4). Two other
patients had normal liver function tests and limited liver ﬁbrosis (Metavir F1). No
patient had chronic liver disease associated to CF. Two patients were diabetic.
Two of the 3 patients were treated during 10−20 weeks with ribavirin, 2 or
3 years after presumed infection. Ribavirin treatment was associated with rapid
normalisation of the liver tests, and negativation of serum HEVRNA viremia after
1−2 months, which remained undetectable 12 months later.
Conclusion: Chronic hepatitis E occurs in lung transplant patients for CF. Diagnosis
has to be suspected, in case of persistent elevated liver enzymes in immunocom-
promised patients. In such patients, HEV diagnosis relies on HEV viremia because
of occurrence of false negative on serology. Liver ﬁbrosis could developed within
few months. Ribavirin treatment has a powerful antiviral effect on HEV.
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Background: Though patients with cystic ﬁbrosis (CF) often suffer from gastro-
intestinal (GI) dysfunction including obstructive symptoms, malabsorption and pain,
the underlying pathophysiology remains obscure.
Aim: To compare GI motility and transit times in CF patients and healthy controls.
Methods: Ten CF patients (ﬁve women, median age 23) with severe mutations.
Total gastrointestinal transit time (GITT) were assessed by radiopaque markers.
Gastric emptying and small intestinal transit were evaluated using the magnet based
Motility Tracking System (MTS-1). With each method patients were compared to16
healthy controls.
Results: Velocity of the magnetic pill through the upper small intestine tended to
be faster in CF patients (median 1.1 cm/min, range 0.7−1.7) compared to controls
(median 1.0 cm/min, range 0.6−1.7) (p= 0.09). However, after seven hours of
recording the pill had reached the cecum in 20% of CF patients while in 88%
of controls (p= 0.001). No statistically signiﬁcant differences were found in median
GITT [CF: 2 days, range 0.5−3.3 versus healthy: 1.5 days, range 0.7−2.5 (p= 0.10)],
gastric emptying time [CF: 58 minutes, range 6–107 versus healthy: 41minutes,
range 4–125 (p= 0.24)].
Conclusion: Passage through the small intestine is delayed in CF patients. Results
indicate particular delay in the distal small intestine.
